idazoxan has been researched along with Huntington Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boulton, RM; Hudson, AL; Nutt, DJ; Pearson, SJ; Reynolds, GP | 1 |
| Chopin, P; Colpaert, F; Marien, M; Martel, J | 1 |
2 other study(ies) available for idazoxan and Huntington Disease
| Article | Year |
|---|---|
Imidazoline binding sites in Huntington's and Parkinson's disease putamen.
Topics: Adrenergic alpha-Antagonists; Brain Chemistry; Humans; Huntington Disease; Idazoxan; Imidazoline Receptors; Parkinson Disease; Putamen; Receptors, Drug | 1996 |
Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Behavior, Animal; Benzofurans; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Enzyme Activation; Huntington Disease; Idazoxan; Imidazoles; Male; Nerve Degeneration; Neuroprotective Agents; Neurotoxins; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 1998 |